GlassScriptPhysician profile
Jodi V Buras
NPI 1265409080
$13,565.35
in general payments reported to CMS, 2019-2025
37 companies · $3,433 in 2025
The $3,433 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,893 · 2022: $2,492 · 2023: $2,942 · 2024: $2,805 · 2025: $3,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,909 · Education: $206 · Consulting Fee: $65.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,908.98 |
| Education | $205.84 |
| Consulting Fee | $65.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,407.83 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $2,219.42 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $2,104.89 | 2021-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $1,574.40 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $896.45 | 2021-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $667.85 | 2021-2025 | Cuvitru, Takhzyro |
| Genzyme Corporation | $666.62 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $497.75 | 2021-2025 | |
| Amgen INC. | $293.12 | 2022-2025 | Tezspire, Tavneos |
| Optinose US, INC. | $283.55 | 2021-2023 | |
| Genentech USA, INC. | $191.94 | 2021-2024 | Xolair |
| Pfizer INC. | $178.46 | 2021-2025 | |
| Blueprint Medicines Corporation | $155.87 | 2022-2025 | Ayvakit |
| Mylan Specialty L.P. | $151.91 | 2022-2024 | Yupelri |
| Abbvie INC. | $132.94 | 2022-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $127.91 | 2021-2022 | |
| Adma Biomanufacturing LLC | $117.67 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.86 | 2021-2022 | |
| Leo Pharma INC. | $105.19 | 2022-2025 | Adbry, Anzupgo |
| Pharming Healthcare, INC. | $91.79 | 2022-2024 | Ruconest |
| Biocryst US Sales Co., LLC | $65.52 | 2022-2025 | Orladeyo |
| Verona Pharma, INC. | $61.52 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $54.14 | 2025 | Yupelri |
| Phadia US INC. | $47.91 | 2021-2024 | Immunocap |
| Kaleo, INC. | $46.46 | 2021-2023 | Auvi-Q |
| Eyevance Pharmaceuticals LLC | $40.11 | 2021 | |
| Galderma Laboratories, L.P. | $34.29 | 2025 | Nemluvio |
| Organon LLC | $34.11 | 2025 | |
| Merck Sharp & Dohme LLC | $33.48 | 2021-2023 | |
| Octapharma USA, INC. | $29.46 | 2024 | Cutaquig |
| Qol Medical, LLC | $26.16 | 2024 | Sucraid |
| Azurity Pharmaceuticals, INC. | $24.32 | 2025 | Alvesco |
| Gc Biopharma USA, INC. | $21.38 | 2025 | Alyglo |
| Kedrion Biopharma, INC. | $20.30 | 2024 | Rhogam Ultra-Filtered Plus, Gammaked, Albuked |
| Incyte Corporation | $20.25 | 2021 | |
| Alk-Abello, INC | $16.53 | 2022 | |
| Hikma Pharmaceuticals USA | $12.99 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Buras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.